COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst ...

With 14 new lawsuits filed and 132 total complaints across 40 states, Novo Nordisk is intensifying efforts to protect ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

This potential loss of strength when taking Ozempic could be a particular concern for adults over the age of 60 who are at a higher risk of muscle loss and reduced mobility.

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

CNBC's Karen Gilchrist discusses Wegovy-maker Novo Nordisk's efforts to regain U.S. market share amid increased competition ...

Even though Novo Nordisk warned that copycat versions of its obesity and diabetes drugs would hurt sales in the U.S., second-quarter sales saw a 67% rise year on year. More news covers telehealth ...

Mr Ratcliffe started on Mounjaro after slowly regaining around 10 stone in weight following a successful Weight Watchers ...

Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...